Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus an...
October 01 2019 - 8:00AM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics, today announced that
Sam Lee, Ph.D., President of Cocrystal, will present data from its
unique structure-based drug design platform technology at the 26th
International Symposium on Hepatitis C Virus and Related Viruses
(“HCV2019”) Conference being held October 5-8, 2019 in Seoul, South
Korea.
The Company's proprietary structure-based drug
discovery technology has demonstrated the ability to design and
develop a high barrier to drug resistance and to be a highly
potent, selective NNI that is active against all HCV genotypes
(1-6) with low level cytotoxicity in multiple cell types.
The details for the Company’s poster
presentation are as follows:
Presenting Author: Sam Lee, Ph.D.
Abstract Title: Development of a novel class of
pan-genotypic HCV inhibitors for HCV combination
therapyPresentation Date: Friday,
October 5, 2019Presentation Time: 5:30 PM
KSTPresentation Session: Vaccines and new
antiviral agents
About the HCV2019
Conference
The Annual ‘International Symposium on Hepatitis
C Virus and Related Viruses’ started in 1994 for advancement of HCV
and related virus research. During the past 25 years, the symposium
has contributed to the understanding of the life cycle of HCV and
related immune responses, and the development of antiviral drugs,
resulting in dramatic improvement in the treatment of hepatitis C.
For more information, please visit the conference website.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication machinery of influenza
viruses, hepatitis C viruses, and noroviruses. Cocrystal employs
unique structure-based technologies and Nobel Prize winning
expertise to create first- and best-in-class antiviral drugs. The
Company is developing CC-31244, an investigational, oral,
broad-spectrum replication inhibitor called a non-nucleoside
inhibitor (NNI). CC-31244 is currently being evaluated in a Phase
2a study for the treatment of hepatitis C as part of a cocktail for
ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered
into an exclusive worldwide license and collaboration agreement
with Merck & Co., Inc. to discover and develop certain
proprietary influenza A/B antiviral agents. CC-42344, the Company’s
molecule for the treatment of influenza A, is currently being
evaluated in preclinical IND-enabling studies. In addition, the
Company has a pipeline of promising early preclinical programs and
continues to identify and develop novel antivirals for the
treatment of norovirus gastroenteritis using the Company’s
proprietary structure-based drug design technology platform. For
further information about Cocrystal, please visit
www.cocrystalpharma.com.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including the prospects for CC-31244, CC-42344 and the Company’s
pipeline of promising preclinical programs. The words "believe,"
"may," "estimate," "continue," "anticipate," "intend," "should,"
"plan," "could," "target," "potential," "is likely," "will,"
"expect" and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to, risks arising from our reliance on continuing
collaboration with Merck under the collaboration agreement, the
availability of products manufactured by third parties, the future
results of preclinical and clinical studies, the research
organization’s inability to recruit subjects and complete the Phase
2a study in a timely manner or at all, including as the result of
civil unrest and political instability in Hong Kong, general risks
arising from clinical trials, receipt of regulatory approvals, our
ability to find and enter into agreements with suitable
collaboration partners, unanticipated litigation and other expenses
and factors that affect the capital markets in general and early
stage biotechnology companies specifically. Further information on
our risk factors is contained in our filings with the SEC,
including our Annual Report on Form 10-K for the year ended
December 31, 2018 and the Form 10-Q for the quarter ended June 30,
2019. Any forward-looking statement made by us herein speaks only
as of the date on which it is made. Factors or events that could
cause our actual results to differ may emerge from time to time,
and it is not possible for us to predict all of them. We undertake
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor and Media
Contact:Jenene Thomas Communications, LLC(833)
475-8247COCP@jtcir.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024